Notice of Special Interest (NOSI): Administrative Supplements to Existing R01 Grants on Polycystic Kidney Disease (PKD)
Notice Number:
NOT-DK-20-031

Key Dates

Release Date:
May 18, 2020
First Available Due Date:
July 15, 2020
Expiration Date:
July 16, 2020

Related Announcements

PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NOT-DK-20-032

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

NIDDK is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators with active NIDDK-supported R01 grants that focus on Polycystic Kidney Disease (PKD) to apply for administrative supplements. The intent of these supplements is to catalyze and accelerate the pace and achievement of scientific research related to PKD. The proposed projects must be within the scope of the currently active R01 award.

Background

Understanding and ameliorating autosomal dominant PKD and autosomal recessive PKD are central to the mission of NIDDK. The clinical course of these diseases is highly variable; some patients develop only a modest number of renal cysts, while others develop a massive number of renal cysts and renal failure at an early age. The diseases have extra-renal manifestations, including in liver and systemic vasculature, with variable penetrance. Despite important advances in elucidating causative genetic defects, many challenges remain in determining other genetic and pathophysiologic mechanisms of PKD that could potentially be targeted for therapeutic interventions. Recognizing the need for interdisciplinary, integrated approaches for identification of novel therapies, this NOSI is issued to catalyze cutting edge research into the causes, pathophysiology and treatment of PKD.

Research Objectives

To catalyze and accelerate the pace and achievement of scientific research related to PKD, the NIDDK is encouraging the submission of applications for Administrative Supplements to active, NIDDK-supported R01 grants focused on PKD. The NIDDK intends to accept applications for supplements under this notice in all scientific areas within the scope of the funded R01 and examples of research areas of interest include, but are not limited to:

  • Studies to identify novel pathogenic pathways and potential translational targets for the treatment of PKD using relevant in vitro and in vivo model systems
  • Studies on factors that determine the severity and progression of PKD
  • Development of mathematical models to identify novel pathways in the pathogenesis of PKD
  • Development of specialized tools, technologies and experimental models for studying PKD
  • Development of models for high throughput screening of promising new therapeutic targets for PKD
  • Recruitment, retention and evaluation of PKD patients using novel methods of phenotyping

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-18-591 must be followed, with the following additions:

  • Application Due Date July 15th, 2020, by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include NOT-DK-20-031 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Requests may be for one year of support only.
  • The budget is limited to $100,000 in direct costs.
  • The Research Strategy section of the application is limited to 6 pages.
  • Only existing awardees of NIDDK-supported R01 grants focused on PKDare eligible to apply.
  • Administrative supplement applications to PA-18-591 must use the application form package with the Competition ID that contains FORMS-F-ADMINSUPP . The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.

Inquiries

Please direct all inquiries to:

Susan Mendley, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-827-1861
Email: susan.mendley@nih.gov

Christine Maric-Bilkan, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-435-0486
Email: christine.maric-bilkan@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices